Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan 18;1(1):CD008951.
doi: 10.1002/14651858.CD008951.pub2.

Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity

Helga Radner  1 , Sofia Ramiro, Rachelle Buchbinder, Robert B M Landewé, Désirée van der Heijde, Daniel Aletaha
Affiliations

Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity

Helga Radner et al. Cochrane Database Syst Rev. .

Abstract

Background: Even with optimal disease-modifying treatment and good control of disease activity, persistent pain due to structural damage is common in people with inflammatory arthritis and therefore additional treatment for pain might be required. Because comorbidity is highly prevalent in people with inflammatory arthritis, it is important to consider comorbidities such as gastrointestinal or liver diseases in deciding upon optimal pharmacologic pain therapy.

Objectives: To assess the efficacy and safety of pharmacological pain treatment in patients with inflammatory arthritis who have gastrointestinal or liver comorbidities, or both.

Search methods: We searched MEDLINE, EMBASE and Cochrane CENTRAL for studies to June 2010. We also searched the 2007-2010 ACR and EULAR abstracts and performed a hand search of reference lists of articles.

Selection criteria: All randomised or quasi-randomised controlled trials (RCTs or CCTs) were considered for inclusion for assessment of efficacy. For safety we also considered single arm trials, controlled before-after studies, interrupted time series, cohort and case-control studies, and case series of 10 or more consecutive cases. Pain therapy comprised paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, opioid-like drugs (tramadol) and neuromodulators (anti-depressants, anticonvulsants and muscle relaxants). The study population comprised adults (>18 years) with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or other spondyloarthritis who had gastrointestinal and/or hepatic comorbid conditions. Outcomes of interest were pain, adverse effects, function and quality of life. Studies that included a mixed population of inflammatory arthritis and other conditions were included only if results for inflammatory arthritis were reported separately.

Data collection and analysis: Two review authors independently selected trials for inclusion, assessed risk of bias and extracted data.

Main results: Out of 2869 articles only one single arm open trial was identified that fulfilled our inclusion criteria. This trial assessed the safety and efficacy of naproxen (dosage not specified) in 58 patients with active rheumatoid arthritis and gastrointestinal comorbidities for up to 52 weeks. Thirteen participants (22%) remained on gold therapy, four participants (10%) remained on hydroxychloroquine, 27 (47%) remained on corticosteroids, 12 (21%) remained on salicylates and all participants continued on antacids and bland diet. The presence of faecal occult blood was reported in 1/58 participants tested between weeks 1 to 26 and 2/32 participants tested between weeks 27 to 52. Over the course of the study, seven participants (12.1%) withdrew due to adverse events but of these, only two participants withdrew due to gastrointestinal side effects (abdominal pain n=1, nausea n=1) and no serious adverse events were reported. Noteable, out of 14 studies excluded due to inclusion of mixed population (osteoarthritis or other rheumatic conditions) or intervention already withdrawn, five trials reported higher risk of developing gastrointestinal events in patients with prior gastrointestinal events when treated with NSAIDs.

Authors' conclusions: On the basis of the current review, there is scant evidence to guide clinicians about how gastrointestinal or liver comorbidities should influence the choice of pain treatment in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or other spondylarthritis. Based upon additional studies that included a mixed population of participants with a range of rheumatic conditions, NSAIDs should be used cautiously in patients with inflammatory arthritis and a history of gastrointestinaI comorbidity as there is consistent evidence that they may be at increased risk.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1
1
Flow chart of the results of the search strategy, outlining the main reasons for study exclusion.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD008951

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Roth 1975 {published data only}
    1. Roth SH, Boost G. An open trial of naproxen in rheumatoid arthritis patients with significant esophageal, gastric, and duodenal lesions. Journal of Clinical Pharmacology 1975;15:378‐84. - PubMed

References to studies excluded from this review

Adam 1991 {published data only}
    1. Adam W. Experiences with 800 mg ibuprofen retard in ambulatory patients with activated osteoarthrosis and extra‐articular rheumatic manifestations [Erfahrungen mit Ibuprofen 800mg retard bei ambulanten Patienten mit aktivierter Osteoarthrose und extraartikularen rheumatischen Beschwerden]. Zeitschrift für Rheumatologie 1991;50:69‐76. - PubMed
Alvart 1983 {published data only}
    1. Alvart R. Multicentre trial of piroxicam in ambulant rheumatology. European Journal of Rheumatology and Inflammation 1983;6:99‐105. - PubMed
Ammitzboll 1979 {published data only}
    1. Ammitzboll F. Fenbufen and Indomethacin in the treatment of rheumatoid arthritis. Scandinavian Journal of Rheumatology 1979;23:5‐10. - PubMed
Andrada 1991 {published data only}
    1. Andrada SS, Rodriguez Valverde V. A double blind randomised controlled trial of droxicam versus indomehtacin in rheumatoid arthritis. European Journal of Rheumatology and Inflammation 1991;11:15‐20. - PubMed
Appelboom 1994 {published data only}
    1. Appelboom T, Franchimont P. Proglumetacin versus indomethacin in rheumatoid arthritis: A double‐blind multicenter study. Advances in Therapy 1994;11(5):228‐34.
Ashcroft 2001 {published data only}
    1. Ashcroft DM, Chapman SR, Clark WK, Millson DS. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib. The Annals of Pharmacotherapy 2001;35(7‐8):829‐34. - PubMed
Bernstein 1992 {published data only}
    1. Bernstein RM, Calin HJ, Calin A, Ollier S. A comparison of the efficacy and tolerability of lornoxicam and indomethacin in ankylosing spondylithis. European Journal of Rheumatology and Inflammation 1992;12:6‐13.
Bombardier 2000 {published data only}
    1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos‐Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. The New England Journal of Medicine 2000;343(21):1520‐8. - PubMed
Burry 1980 {published data only}
    1. Burry HC, Sibers R. A comparison of flurbiprofen with naproxen in ankylosing spondylitis. The New Zealand Medical Journal 1980;92:309‐11. - PubMed
Busson 1986 {published data only}
    1. Busson M. A long‐term study of flurbiprofen in rheumatological disorders: I Rheumatoid arthritis. Journal of International Medical Research 1986;14:1‐6. - PubMed
Cardoe N 1977 {published data only}
    1. Cardoe N, Fowler PD. Butacote: A six‐year follow‐up of patients with gastric intolerance to other medications. Journal of International Medical Research 1977;5(2):59‐66. - PubMed
Caruso 1994 {published data only}
    1. Caruso I, Monrone F, Boari L, Davoli C, Fiorentini F. Lornoxicam versus diclofenac in rheumtoid arthritis: A double‐blind multicenter study. Advances in Therapy 1994;11(3):133‐8.
Castellsague 2009 {published data only}
    1. Castellsagugue J, Holick CN, Hoffmann CC, Perez‐Gutthann. Risk of upper gastrointestinal complications associated with cyclooxygenase‐2‐selective and nonselective nonsteroidal antiinflammatory drugs. Pharmacotherapy 2009;29:1397‐407. - PubMed
Chan 2002 {published data only}
    1. Chan FKL, Hung LCT, Suen BY, Wu JCY, Lee KC, Leung VKS, Hui AJ, To KF, W.K Leung WK, Wong VKS, Chung S, Sung JYY. Celecoxib versus diclofenac and omeprazol in reducing the risk of recurrent ulcer bleeding in patients with arthritis. The New England Journal of Medicine 2002;347(26):2104‐10. - PubMed
Chan 2004 {published data only}
    1. Chan FKL, Hung LCT, Suen BY, Wong VWS, Hui AJ, Wu JCY, Leung WK, Lee YT, To KF, Chung SCS, Sung JJY. Celecoxib versus diclofenac plus omeprazole in high risk arthritis patients: Results of a randomized double‐blind trial. Gastroenterology 2004;127:1038‐43. - PubMed
Chan 2010 {published data only}
    1. Chan FKL, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376(9736):173‐9. - PubMed
Degner 2000 {published data only}
    1. Degner F, Sigmund R, Zeidler H. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clinical Therapeutics 2000;22(4):400‐10. - PubMed
de Melo Gomes 1992 {published data only}
    1. Melo Gomes JA. The safety of arthrotec in patients with rheumatoid arthritis or osteoarthritis: An assessment of the upper gastrointestinal tract by endoscopy. Scandinavian Journal of Rheumatology 1992;96:23‐31. - PubMed
Doggrell 2005 {published data only}
    1. Doggrell SA. The safety of lumiracoxib when used in the treatment of arthritis. Expert Opinion on Pharmacotherapy 2005;6:347‐50. - PubMed
Eisen 2005 {published data only}
    1. EIsen GM, Goldstein JL, Hanna DB, Rublee DA. Meta‐analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase‐2‐specific inhibitor, compared with nonspecific nonsteroidal anti‐inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Alimentary Pharmacology and Therapeutics 2005;21:591‐8. - PubMed
El Miedany 2006 {published data only}
    1. Miedany Y, Yousef S, Ahmed I, Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox‐2 inhibitor in inflammatory bowel disease. American Journal of Gastroenterology 2006;101:311‐7. - PubMed
El‐Serag 1997 {published data only}
    1. El‐Serag HB, Sonnenber A. Association of esophagitis and esophageal strictures with diseases treated with nonsteroidal anti‐inflammatory drugs. The American Journal of Gastroenerology 1997;92(1):52‐6. - PubMed
Emery 1999 {published data only}
    1. Emery P, Zeidler H, Kvien TK, Geis GS. Celecoxib versus diclofenac in long‐term management of rheumatoid arthritis: randomised double‐blind comparison. Lancet 1999;354:2106‐11. - PubMed
Eversmeyer 1993 {published data only}
    1. Eversmeyer W, Poland M, DeLapp RE, Jensen CP. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. The American Journal of Medicine 1993;95:10‐8. - PubMed
Fenton 1988 {published data only}
    1. Fenton SF, Ryan JP, Bensen WG. A double‐blind, crossover, multicenter study of piroxicam and naproxen in rheumatoid arthritis. Current Therapeutic Research 1988;66(6):1058‐70.
Fossgreen 1976 {published data only}
    1. Fossgreen J, Kirchheiner B, Pertersen FO, Tophoj E, Zachariae E. Clinical evaluation of ketoprofen in rheumatoid arthritis. Scandinavian Journal of Rheumatology 1976;14 Suppl:93‐8. - PubMed
Franssen MJ {published data only}
    1. Franssen MJAM, Grinbnau FWJ, Putte LBA. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. Clinical Rheumatology 1986;5(2):210‐20. - PubMed
Furst 2002 {published data only}
    1. Furst DE, Karen S, Kolba KS, Fleischmann R, Roszko PJ. Dose response and safety study of meloxicam up to 22.5mg daily in rheumatoid arthritis: A 12 week mulitcenter, double blind, dose response study versus placebo and diclofenac. The Journal of Rheumatology 2002;29(3):436‐46. - PubMed
Geis 1993 {published data only}
    1. Geis GS. Arthrotec: A therapeutic option in the management of arthritis. European Journal of Rheumatology and Inflammation 1993;13:25‐32. - PubMed
Goldstein 2000 {published data only}
    1. Goldstein JL, Fred E, Silverstein MD, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX‐2‐inhibitor. The American Journal of Gastroenterology 2000;95(7):1681‐90. - PubMed
Goldstein 2004 {published data only}
    1. Goldstein JL, Eisen GM, Agrawal N, Stenson WF, Kent JD, Verburg KM. Reduced incidence of upper gastrointestinal ulcer complications with the COX‐2 selective inhibitor, valdecoxib. Alimentary Pharmacology and Therapy 2004;20:527‐38. - PubMed
Graziano 1991 {published data only}
    1. Graziano FM. Once‐daily or twice daily administration of naproxen in patients with rheumatoid arthritis. Clinical Therapeutics 1991;13:20‐5.
Grennan 1977 {published data only}
    1. Grennan DM. Therapeutic uses of azapropazone. Scottish Medical Journal 1977;22:22‐4. - PubMed
Hernández‐Diaz 2010 {published data only}
    1. Hernández‐Diaz S, Garcia Rodriguez A. Association between nonsteroidal anti‐inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Archives of Internal Medicine 2010;160:2093‐9. - PubMed
Howard 1978 {published data only}
    1. Howard DLG. A double‐blind crossover evaluation of ketoprofen and placebo in rheumatoid arthritis with assessment of long‐term tolerance. The Journal of International Medical Research 1978;6:300‐5. - PubMed
Hunter 1996 {published data only}
    1. Hunter JA, Parnham MJ, Balaguer I. Aceclofenac in rheumatoid arthritis: a useful and novel anti‐Inflammatory. Clinical Rheumatology 1996;15(4):329‐34. - PubMed
Huskisson 1991 {published data only}
    1. Huskisson EC, Scott DL. A clinical comparison of two leading non‐steroidal anti‐inflammatory drugs. European Journal of Rheumatology and Inflammation 1991;11:4‐7. - PubMed
Huskisson 1996 {published data only}
    1. Huskisson EC, Ghozlan R, Kurthen R, Degners FL, Bluhmki E. A long‐term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. British Journal of Rheumatology 1996;35 Suppl 1:29‐34. - PubMed
Jajic 2005 {published data only}
    1. Jajic Z, Malaise M. Nekam K, Koó E, Dankó K, Kovacs M, Scarpignato C. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2005;23:809‐18. - PubMed
Karateev 2008 {published data only}
    1. Karateev AE. Relapses of NSAID‐induced ulcers in rheumatologic patients who continue treatment with NSAIDs (meeting abstract). Annals of Rheumatic Disease 2008;67 Suppl II:170.
Kean 1993 {published data only}
    1. Kean W, Buchanan W, Pelletier JP, Haraoui B, Choquette D, Senecal JL, Gascon J, Germain H, Menard H, Huang S, Elie R, Gerecz‐Simon E. Open study on the efficacy and safety of long‐term use of surgam‐sr (sustained‐release form of tiaprofenic acid) in rheumatoid arthritis patients. Inflammopharmacololgy 1993;2:63‐70.
Kennedy 1991 {published data only}
    1. Kennedy AC, Germain BF, Goldman AL, Vreede PD. A double‐blind crossover compariosn of ketoprofen and indomethacin in ankylosing spondylitis. Advances in Therapy 1991;8(3):148‐56.
Koppes 1974 {published data only}
    1. Koppes GM, Arnett FC. Salicylate hepatotoxicity. Postgraduate Medicine 1974;56:193‐5. - PubMed
Krueger 2008 {published data only}
    1. Krueger K, Lino L, Dore R. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs. diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE II). Annals of Rheumatic Diseases 2008;67:315‐22. - PubMed
Laine 2002 {published data only}
    1. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A. Stratifying the risk of NSAID‐related upper gastrointestinal clinical events: Results of a double‐blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006‐12. - PubMed
Laine 2006 {published data only}
    1. Laine L, Smith R, Min K, Chen Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non‐steroidal anti‐inflammatory drugs. Alimentary Pharmacology and Therapy 2006;24:751‐67. - PubMed
Laine 2007 {published data only}
    1. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Mulinational Etoricoxib and Diclofenac Arthritis Long‐term (MEDAL) programme: a randomised comparison. Lancet 2007;369:465‐73. - PubMed
Laine 2008 {published data only}
    1. Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP. Lower gastrointestinal events in a double‐blind trial of the cyclo‐oxygenase‐2‐selective inhibitor etoricoxib and the traditional nonsteroidal anti‐inflammatory crug diclofenac. Gastroenterology 2008;135:1517‐25. - PubMed
Lazzaroni 2007 {published data only}
    1. Lazzaroni M, Battocchia A, Bianchi Porro G. COXIBs and non‐selective NSAIDs in the gastroenterological setting: what should patients and physicians do?. Digestive and Liver Disease 2007;39:589‐96. - PubMed
Lehtinen 1987 {published data only}
    1. Lehtinen K. A six‐month follow‐up study of a slow‐release indomehtacin tablet in rheumatic diseases. Clinical Rheumatology 1987;6:606‐7. - PubMed
Lisse JR {published data only}
    1. Lisse JR. Clinical efficacy and safety of naprelan versus naprosyn in the treatment of rheumatoid arthritis. American Journal of Orthopedics 1996;25:21‐9. - PubMed
Lussier 1976 {published data only}
    1. Lussier A, Camerlain M, Menard H, Myhal D, Wehner S. A double blind cross‐over evaluation of ketorprofen and aspirin in rheumatoid arthritis. Scandinavian Journal of Rheumatology 1976;14 Suppl:99‐104. - PubMed
Magaro 1989 {published data only}
    1. Magaro M, Altomonte L, Zoli A, Mirone L, Berchicci MC, Tricerri A, Corvino G. Asymptomatic and symptomatic gastroduodenal patients affected by rheumatic disease treated with non‐steroidal anti‐inflammatory drugs. Panminerva Medica 1989;31:16‐8. - PubMed
Manniche 1987 {published data only}
    1. Manniche C, Malchow‐Moller A, Andersen JR, Pedersen C, Hansen TM, Jess P, et al. Randomised study of the influence of non‐steroidal anti‐inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease. Gut 1987;28(2):226‐9. - PMC - PubMed
Muller‐Fassbender 1975 {published data only}
    1. Muller‐Fassbender A. A long‐term study of benorylate in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 1976;13:21‐4. - PubMed
Niculescu 2009 {published data only}
    1. Niculescu L, Li C, Huang J, Mallen S. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Current Medical Research and Opinions 2009;25(3):729‐40. - PubMed
Nielsen 2006 {published data only}
    1. Nielsen OH, Ainsworht M, Csillag C, Rask‐Madsen J. Systematic review: coxibs, non‐steroidal anti‐inflammatory drugs or non cyclo‐oxygenase inhibitors in gastroenterological high risk patients. Alimentary Pharmacology and Therapy 2006;23:27‐33. - PubMed
O´Brien 1976 {published data only}
    1. O'Brien W, Grunwaldt E. Ketoprofen in the treatment of rheumatoid arthritis: double blind cross‐over placebo comparison. Scandinavian Journal of Rheumatology 1976;14 Suppl:105‐10. - PubMed
Perez‐Ruiz 1996 {published data only}
    1. Perez‐Ruiz F, Alonso‐Ruiz A, Ansoleaga JJ. Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. Clinical Rheumatology 1996;15:473‐7. - PubMed
Porkodi 1987 {published data only}
    1. Porkodi R, Raghuram K, Parthiban M, Chandrasekaran AN. Therapeutic efficacy and gastric tolerance of ibuprofen at 1600‐2400 mg dosage in rheumatoid arthritis. The British Journal of Clinical Practice 1987;41(12):1037‐40. - PubMed
Rahme 2007 {published data only}
    1. Rahme E, Nedjar H. Risk and benefits of COX‐2‐inhibitors vs non‐selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology 2007;46:435‐8. - PubMed
Reinisch 2003 {published data only}
    1. Reinisch W, Miehsler W, Dejaco C, Harrer M, Waldhofer T, Lichtenberger, Vogelsang H. An open‐label trial of the selective cyclo‐oxygenase 2 inhibitor rofecoxib in inflammatory bowel disease associated peripheral arthritis and arthralgia. Alimentary Pharmacology and Therapy 2003;17:1371‐80. - PubMed
Richy F {published data only}
    1. Richy F, Scarpignato C, Lanas A. Efficacy and safety of piroxicam revisited: a global meta‐analysis of randomised control trials. Pharmacological Research 2009;60:254‐63. - PubMed
Rooney 1974 {published data only}
    1. Rooney PJ, Watkins C, Ahola SJ, Gray GIL, Carson DW. A short‐term double blind controlled trial of prenazone (DA2370) in rheumatoid arthritis. Current Medical Research and Opinion 1974;2:43. - PubMed
Rostom 2005 {published data only}
    1. Rostom A, Goldkind L, Laine L. Nonsteroidal anti‐inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clinical Gastroenterology and Hepatology 2005;3:489‐98. - PubMed
Roth 1976 {published data only}
    1. Roth SH, Englund DW, Harris BK. Longterm fenoprofen therapy in patients with rheumtoid arthritis. Journal of Rheumatology 1976;2:43‐8. - PubMed
Roth 1995 {published data only}
    1. Roth SH, Bennett SE, Caldron PH, Mitchell CS, Swenson CM. Endoscopic evaluation of the long term effects of diclofenac sodium and naproxen in elderly patients with arthritis. Clinical Drug Investigation 1995;9(3):171‐7.
Schmid 1976 {published data only}
    1. Schmid FR, Culic DD. Anti‐inflammatory drugs and gastrointestinal bleeding: a comparison of aspirin and ibuprofen. Journal of Clinical Pharmacology 1976;16:418‐25. - PubMed
Seidman 1988 {published data only}
    1. Seideman P, Eriksson LO. Indomethacin in rheumatoid arthritis. Clinical Trials Journal 1988;25(5):349‐58.
Seissiger 1987 {published data only}
    1. Seissiger L, Dell HD. Acetaminophen in patients with rheumatic disease with concomitant liver diseases: pharmacokinetics, effectiveness and tolerance [Acemetacin bei rheumapatienten mit leberbegleiterkrankungen pharmakokinetik, wirksamkeit und verträglichkeit]. Zeitschrift für Rheumatologie 1987;46(Suppl 1):65‐9. - PubMed
Simon 1987 {published data only}
    1. Simon B, Dammann HG, Müller P. Stomach tolerance of nonsteroidal antirheumatic drugs: comparative endoscopic study [Magenverträglichkeit nichtsteroidaler antirheumatika: endoskopische vergleichsstudien]. Zeitschrift für Rheumatologie 1987;46(Suppl.1):40‐6. - PubMed
Simpson 1989 {published data only}
    1. Simpson J, Golding DN, Freeman AM, Cooke D, Hooper PA, Jamieson V, Osborne C. A large multicentre, parallel group, double‐blind study comparing tenoxicam and piroxicam in the treatment of osteoarthritis and rheumatoid arthritis. British Journal of Clinical Practice 1989;43:328‐33. - PubMed
Singh 1996 {published data only}
    1. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti‐inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Archives of Internal Medicine 1996;156(14):1530‐6. - PubMed
Soni 2009 {published data only}
    1. Soni P, Shell B, Cawkwell G, Li C, Ma H. The hepatic safety and tolerability of the cyclooxgenase‐2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. Current Medical Research and Opinion 2009;25(8):1841‐51. - PubMed
Tausch 1976 {published data only}
    1. Tausch G, Bröll H, Dunky A, Eberl R. Comparative clinical trial with a new substance, diftalone, versus indomethacin in 30 patients with rheumatoid arthritis. Scandanavian Journal of Rheumatology 1976;5:145‐50. - PubMed
Teule 1986 {published data only}
    1. Teule M. Double‐blind comparative multicenter study of the efficacy and safety of a slow release tablet of 200 mg ketoprofen once daily and a 50mg ketoprofen capsule four times daily. Current Therapeutic Research 1986;40(6):1129‐46.
Turner 1988 {published data only}
    1. Turner R. Hepatic and renal tolerability of long‐term naproxen treatment in patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism 1988;17(3):29‐35. - PubMed
Watson 2004 {published data only}
    1. Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ. The upper gastrointestinal safety of rofecoxib versus NSAIDs: an updated combined analysis. Current Medical Research and Opinion 2004;20(10):1539‐48. - PubMed
Wollheim 1978 {published data only}
    1. Wollheim FA, Lindroth Y, Sjöblom K. A comparison of ketoprofen and naproxen in rheumatoid arthritis. Rheumatology and Rehabilitation 1978;Suppl:78‐83. - PubMed
Wong 2008 {published data only}
    1. Wong WSV, Chan FKL. Cyclooxygenase‐2‐inhibitors in patients with high gastrointestinal risk: are we there yet?. Journal of Gastroenterololgy 2009;44 Suppl XIX:53‐6. - PubMed
Zutshi 1976 {published data only}
    1. Zutshi D, Mason M. Ketorprofen in rheumatoid arthritis: its tolerance and therapeutic effect. Scandinavian Journal of Rheumatology 1976;14 Suppl:77‐84. - PubMed

Additional references

Akarca 2005
    1. Akarca US. Gastrointestinal effects of selective and non‐selective non‐steroidal anti‐inflammatory drugs. Current Pharmaceutical Design 2005;11(14):1779‐93. - PubMed
Benson 1983
    1. Benson GD. Hepatotoxicity following the therapeutic use of antipyretic analgesics. American Journal of Medicine 1983;14(75):85‐93. - PubMed
Benson 2005
    1. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. American Journal of Therapeutics 2005;12(2):133‐41. - PubMed
Bergmann 2006
    1. Bergmann MJ. Social and economic impact of inflammatory arthritis. Postgraduate Medicine 2006;Spec No:5‐11. - PubMed
Boswell 2010
    1. Boswell K, Kwong WJ, Kavanagh S. Burden of opioid‐associated gastrointestinal side effects from clinical and economic perspectives: a systematic literature review. Journal of Opioid Management 2010;6(4):269‐89. - PubMed
Briggs 2009
    1. Briggs A, March L, Reid C, Lassere M, Reid C, Henderson L, et al. Baseline comorbidities in an Australian population‐based cohort of rheumatoid arthritis patients receiving biological therapy: Data from the Australian Rheumatology Association Database (ARAD). International Journal of Rheumatology. 2009. - PMC - PubMed
Calin 1994
    1. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. Journal of Rheumatology 1994;21(12):2281‐5. - PubMed
Cook 2008
    1. Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population‐based survey. Alimentary Pharmacology and Therapy 2008;27(12):1224‐32. - PubMed
CRD 2001
    1. Khan KS, ter Riet G, Popay J, Nixon N, Kleijnen J. Study quality assessment. Undertaking Systematic Reviews of Research on Effectiveness. CRD's guidance for those carrying out or commissioning reviews. Report 4. York Publishing Services Ltd, March 2001.
da Silva 2001
    1. Silva JA, Ramiro S, Pedro S, Rodrigues A, Vasconcelos JC, Benito‐Garcia E. Patients‐ and physicians‐ priorities for improvement. The case of rheumatic diseases. Acta Reumatologica 2001;35(2):192‐9. - PubMed
DeAngelis 2004
    1. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA 2004;292(11):1363‐4. - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Chichester (UK): John Wiley & Sons.
Doward 2003
    1. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Annals of Rheumatic Disease 2003;62:20‐6. - PMC - PubMed
Drossaers‐Bakker 1999
    1. Drossaers‐Bakker KW, Buck M, Zeben D, Zwinderman AH, Breedveld FC, Hazes JMW. Long‐term course and outcome of functional capacity in rheumatoid arthritis ‐ The effect of disease activity and radiologic damage over time. Arthritis and Rheumatism 1999;42:1854‐60. - PubMed
Emery 2006
    1. Emery P. Treatment of rheumatoid arthritis. BMJ 2006;332:152‐5. - PMC - PubMed
EPOC 2008
    1. EPOC data collection checklist. http://epoc.cochrane.org/epoc‐resources‐review‐authors.
Fries 1980
    1. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis and Rheumatism 1980;23(2):137‐45. - PubMed
Gabriel 1999
    1. Gabriel SE. Comorbidity in arthritis. Journal of Rheumatology 1999;26:2475‐9. - PubMed
Heiberg 2002
    1. Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis and Rheumatism 2002;47(4):391‐7. - PubMed
Henry 2003
    1. Henry D, McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. International Journal of Clinical Practice 2003;135:43‐9. - PubMed
Higgins 2011a
    1. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editors, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration.
Higgins 2011b
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011c
    1. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011 ). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration.
Jong 1997
    1. Jong Z, Heijde D, McKenna SP, Whalley D. The reliability and construct validity of the RAQoL: a rheumatoid arthritis‐specific quality of life instrument. British Journal of Rheumatology 1997;36(8):878‐83. - PubMed
Marks 2010
    1. Marks JL, Colebatch AN, Buchbinder R, Edwards CJ. Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD008952.pub2] - DOI - PubMed
Michaud 2007
    1. Michaud K. Comorbidities in rheumatoid arthritis. Best Practice & Research in Clinical Rheumatology 2007;21(5):885‐906. - PubMed
Mikulis 2003
    1. Mikuls TR. Co‐morbidity in rheumatoid arthritis. Best Practice & Research in Clinical Rheumatology 2003;17(5):729‐52. - PubMed
Minnrock 2003
    1. Minnock P, FitzGerald O, Bresnihan B. Women with established rheumatoid arthritis perceive pain as the predominant impairment of health status. Rheumatology 2003;42(8):995‐1000. - PubMed
Moore 2010
    1. Moore AR, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, McQuay H. ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief; Cochrane Pain, Palliative and Supportive Care Systematic Review Group Editors. "Evidence" in chronic pain‐‐establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386‐9. - PubMed
Ng 2010
    1. Ng SC, Chan FK. NSAID‐induced gastrointestinal and cardiovascular injury. Current Opinion in Gastroenterology 2010;26(6):611‐7. - PubMed
Oldroyd 2009
    1. Oldroyd J, Schachna L, Buchbinder R, Staples M, Briggs A, Lassere M, Reid C, March L. Baseline characteristics in an Australian population‐based cohort of patients with ankylosing spondylitis commencing biological therapy: data from the Australian Rheumatology Association Database (ARAD). International Journal of Rheumatology. 2009. - PMC - PubMed
Pincus 1983
    1. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis and Rheumatism 1983;26(11):1346‐53. - PubMed
Prescott 2000
    1. Prescott LF. Paracetamol, alcohol and the liver. British Journal of Clinical Pharmacology 2000;49(4):291‐301. - PMC - PubMed
Schünemann 20011b
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration.
Schünemann 2011a
    1. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration.
Silverstein 2000
    1. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti‐inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long‐term Arthritis Safety Study. JAMA 2000;284(13):1247‐55. - PubMed
Simon 1999
    1. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti‐inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.. JAMA 1999;282(20):1921‐8. - PubMed
Singh 1999
    1. Singh G, Triadafilopoulos G. Epidemiology NSAID induced gastrointestinal complications. Journal of Rheumatology 1999;26 Suppl 56:18‐24. - PubMed
Smolen 2010
    1. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs. Annals of Rheumatic Disease 2010;69(6):964‐75. - PMC - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration.
Ware 1992
    1. Ware JE, Sherbourne CD. The Mos 36‐Item Short‐Form Health Survey (SF‐36). 1. Conceptual‐Framework and Item Selection. Medical Care 1992;30:473‐83. - PubMed
Wells 2008
    1. Wells GA, Shea B, O'Connell D, et al. The Newcastle‐Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta‐analyses. Available from: URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm 2009.
Wolfe 1999
    1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. New England Journal of Medicine 1999;340:1888‐99. - PubMed

Publication types

MeSH terms

Substances